Innovative screening methods to reduce the misdiagnosis of Lyme disease: Public health and global implications
Lyme disease remains a persistent global health concern, complicated by diagnostic delays and high rates of misdiagnosis, particularly in early-stage presentations and underserved populations. Conventional two-tier serological testing is hampered by limited sensitivity, antigenic cross-reactivity, a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | The Microbe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950194625001347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Lyme disease remains a persistent global health concern, complicated by diagnostic delays and high rates of misdiagnosis, particularly in early-stage presentations and underserved populations. Conventional two-tier serological testing is hampered by limited sensitivity, antigenic cross-reactivity, and poor performance in acute disease. Recent advancements in diagnostic innovation, including Modified Two-Tier Testing (MTTT), synthetic peptide-based platforms, bacteriophage-targeted PCR, and MENSA (Medium Enriched for Newly Synthesized Antibodies), offer enhanced sensitivity, specificity, and real-time immune profiling. In parallel, developments in therapeutic and preventive strategies, such as cyclic antimicrobial peptides and microbiota-targeted vaccines, underscore a growing emphasis on translational approaches to persistent infection and vector control. This review provides a novel synthesis of diagnostic and therapeutic advances in Lyme disease, uniquely bridging molecular tools, public health disparities, and precision medicine. |
|---|---|
| ISSN: | 2950-1946 |